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Prions are infectious agents which cause rapidly lethal neurode-
generative diseases in humans and animals following long, clini-
cally silent incubation periods. They are composed of multichain
assemblies of misfolded cellular prion protein. While it has long
been assumed that prions are themselves neurotoxic, recent devel-
opment of methods to obtain exceptionally pure prions from mouse
brain with maintained strain characteristics, and in which defined
structures—paired rod-like double helical fibers—can be definitively
correlated with infectivity, allowed a direct test of this assertion. Here
we report that while brain homogenates from symptomatic prion-
infected mice are highly toxic to cultured neurons, exceptionally pure
intact high-titer infectious prions are not directly neurotoxic. We fur-
ther show that treatment of brain homogenates from prion-infected
mice with sodium lauroylsarcosine destroys toxicity without diminish-
ing infectivity. This is consistent with models in which prion propa-
gation and toxicity can be mechanistically uncoupled.
prions | neurotoxicity | neurodegeneration
Prion diseases are fatal transmissible neurodegenerative con-ditions affecting humans and a range of other mammalian
species (1, 2). Infectious prions are composed of multichain as-
semblies of misfolded host-encoded cellular prion protein (PrPC)
which propagate by recruitment of further PrPC and subsequent
fission (1, 3–5). Multiple studies have demonstrated neurotox-
icity of crude or semipurified preparations of brain homogenate
from prion-infected animals in cultured primary mouse neurons
or mouse brain slices in vitro (6–10). However, prion infections
are associated with accumulation of a diverse range of PrP as-
semblies, only a minority of which meet the biochemical definition
(with characteristic resistance to proteinase K [PK] digestion) of
PrPSc, a term often used synonymously with prion infectivity (1,
11–14). We have previously demonstrated that, following an initial
phase of exponential prion propagation in vivo, which is not rate-
limited by PrPC expression level, infective titer reaches a plateau
level, and the duration of this plateau phase to clinical onset is
inversely proportional to PrPC expression level (15). During this
plateau phase there is accumulation of protease-sensitive disease-
related forms of PrP at a rate linearly proportional to the PrPC
expression level (14). It is during this second phase that neuro-
pathology becomes established. We propose that a toxic PrP
species, PrPL, is generated during this phase with clinical onset
occurring when PrPL reaches a neurotoxic threshold (3, 14). This
model proposes that infectious prions are themselves not toxic but
that a pathway switch to production of PrPL once a plateau level of
infectivity is reached is responsible for the synaptotoxicity and
neurodegeneration that leads to clinical onset (3, 14, 15). This
model is also supported by the recognition of subclinical prion
infections where animals may live a normal life span despite
harboring high prion titers in their brains (16–19).
A major obstacle to defining the neurotoxic PrP species has been
the development of a suitable in vitro assay with sufficient dynamic
range that will readily discriminate between normal and prion-infected
brain. Here we report a multiparametric assay of neuronal morphol-
ogy and show that neurite length, neurite fragmentation, and dendritic
spine density unequivocally differentiate prion-infected from nonin-
fected mouse brain toxicity. Remarkably, highly purified mouse prions
(20–22) show no toxic response in this assay. Moreover, we show
that treatment of brain homogenates from prion-infected mice
with sodium lauroylsarcosine (≥2% [wt/vol] final concentration)
destroys toxicity without reducing the prion infectivity titer,
thereby clearly demonstrating that infectious prion assemblies can
be uncoupled from neurotoxicity. The advances reported here will
facilitate isolation of the neurotoxic PrP species and its structural
characterization.
Results
Purified Rocky Mountain Laboratory Prions Are Not Neurotoxic in Cell
Culture.We isolated prions from the brains of clinically sick mice
that had been intracerebrally inoculated with the Rocky Moun-
tain Laboratory (RML) prion strain using an established method
to isolate exceptionally pure high-titer prions (20). This method
maintains the strain properties of RML prions, and the specific
infectivity of such purified RML prions (pRML) was accurately
determined by Automated Scrapie Cell Assay (ASCA) (23).
The infectious titer of the pRML stock solutions prepared in
Dulbecco’s phosphate-buffered saline (D-PBS) was 107.9 ± 0.2
infectious units (IU)/mL with a specific prion infectivity of
109.5 ± 0.2 IU/mg protein.
Significance
Prions are infectious agents composed of polymers of mis-
folded prion protein which cause fatal brain diseases such as
Creutzfeldt–Jakob disease. These diseases involve progressive
loss of neuronal cells, and it has been long assumed that prions
are directly toxic to cells as they propagate. However, recent
studies have suggested that prion infectivity and neurotoxicity
can be uncoupled and involve distinct mechanisms. Using
highly purified infectious prions we demonstrate that prions
are not directly neurotoxic and that toxicity present in infected
brain tissue can be distinguished from infectious prions. This
has fundamental implications for understanding of prion dis-
eases and how to treat them and may have wide relevance in
other neurodegenerative diseases which involve propagation
and spread of proteopathic seeds.
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We assessed neurotoxicity of pRML in a high-throughput, mul-
tiparametric assay consisting of time-course studies and end-point
analyses of neuronal morphology. Neurite retraction was measured
in phase-contrast mode in a cortico-hippocampal mouse neuronal
culture on an IncuCyteS3 live-cell imaging platform followed by
immunocytochemistry and high-content image analysis of neurons
on an Opera Phenix platform. For immunostaining we used the
neuron-specific markers NeuN, MAP2, and spinophilin that de-
tected neuronal nuclei, neurites, and dendritic spines, respectively.
We first examined toxicity of RML prion-infected and normal,
uninfected, brain homogenate in these assays. Brain homogenate
dilutions from clinically sick RML prion-infected wild type (Prnp+/+)
mice containing from 104.2 to 105.7 IU/mL showed marked neuro-
toxicity (Figs. 1–4 and Movies S1 and S2) and, although normal brain
homogenate at higher concentrations also showed nonspecific toxic
effects, this was never comparable to the extent of toxicity elicited by
RML-infected brain homogenate. Indeed, when applied over a range
of equivalent concentrations, RML-infected brain homogenate was
always significantly more toxic than normal brain homogenate (Figs.
1–4 and SI Appendix, Fig. S2, andMovies S1 and S2). Importantly, no
significant prion propagation was detected by ASCA in primary
mouse neurons treated with infectious RML brain homogenates for
72 h (SI Appendix, Fig. S1), indicating that prion propagation was not
the basis for the observed specific neurotoxicity. In sharp contrast to
findings with RML-infected brain homogenate, pRML prions, di-
luted in tissue culture medium, did not induce neurite retraction even
when as much as 106.7 IU/mL was added, equivalent to a 10-fold
higher prion titer than that present in the brain homogenate eliciting
maximal toxicity (Fig. 2 A and B). We also evaluated neurite frag-
mentation (Fig. 2C) and dendritic spine density (Fig. 2 D and E) and
found that none of the pRML preparations induced toxicity in
the cultured neurons at any stage of treatment, again in sharp
contrast to RML prion-infected brain homogenate (Fig. 2 and
Movie S3).
Purified RML Prions in Prnp0/0 Mouse Brain Homogenate Are Not
Neurotoxic in Cell Culture. It is possible that, in order to cause
neurotoxicity, infectious prions require cofactors present in mouse
brain. Therefore we resuspended pRML prions in brain homog-
enate from uninfected Prnp0/0 mice (which are devoid of PrPC and
unable to propagate prions) (24, 25). We tested four concentra-
tions of infectious pRML containing 104.2 to 106.7 IU/mL using the
above-described multiparametric assay of neurotoxicity. As with
pRML prions in tissue culture media, pRML prions diluted in
Prnp0/0 brain homogenate prior to application to neurons showed
no evidence of neurotoxicity as measured by neurite retraction
(Fig. 3 A and B, and Movie S4), neurite fragmentation (Fig. 3C),
or reduction in spine density (Fig. 3 D and E). Prnp0/0 brain ho-
mogenate itself at a concentration of 10−4 did not cause toxicity in
primary neurons, whereas RML prion-infected brain at the same
concentration was toxic (Fig. 3 B–E, and Movies S1 and S5).
Purified RML Prions in Prnp+/+ Mouse Brain Homogenate Are Not
Neurotoxic in Cell Culture. We also added pRML to brain ho-
mogenate from uninfected wild-type Prnp+/+ mice to levels of
104.2 to 106.7 IU/mL and applied it to primary neurons for 3 d as
before. As incubation of pRML prions with Prnp+/+ brain ho-
mogenate could conceivably result in generation of prions or pu-
tative toxic PrP species in vitro prior to addition to the neuronal
culture, we kept incubation time to a minimum and did not exceed







































































Fig. 1. Development of the IncuCyte-based neurite retraction assay. (A and B) Neurite outgrowth in primary neurons plated at 15,000 cells/well plateaued
after 10 d in vitro (DIV); n = 6. Dark blue traces: neurites; yellow: cell features excluded from neurite analysis. (Scale bar, 200 μm.) (C) Neurite retraction in
response to the treatment with RML-infected and uninfected Prnp+/+ brain diluted to a concentration of 10−3 (RML, 105.2 IU/mL) for 12 h occurred in a cell-
density–dependent manner (n = 3, *P < 0.03, unpaired two-tailed t test). (D) Dose–response curve for the neurite retraction assay; n = 3 to 12 independent cell
cultures were analyzed in triplicate after 12 h of treatment; mean ± SD. Data were fitted using a nonlinear regression model [Y = 100/(1+10^((LogIC50-
X)×HillSlope))]. ****P < 0.0001, one-way ANOVA with Tukey’s multiple comparison test.























10 min at 37 °C. Normal brain homogenate at 10−4 concentration
was selected as the vehicle for these spiking experiments because
at this concentration there is minimal nonspecific toxicity, and the
dynamic sensitivity of the assay to report potential toxicity of
pRML is maximal (Figs. 3 and 4, and Movies S1, S2, and S4–S6).
Four concentrations of pRML diluted in Prnp+/+ brain homoge-
nate were tested. We did not observe neurite retraction even at
the highest titer of infectious pRML (106.7 IU/mL) in Prnp+/+
brain homogenate, equivalent to a 10-fold higher prion titer than
that present in the brain homogenate eliciting maximal toxicity
(Figs. 4A and 2B and Movie S6). Furthermore, no neurite frag-
mentation or dendritic spine loss was observed (Fig. 4 C–E). In
sharp contrast, 10% (wt/vol) RML prion-infected brain homoge-
nate diluted to 104.2 IU/mL caused marked neurite fragmentation
and spine loss (Fig. 4 C and D). Further experiments using a higher
concentration of normal brain homogenate as vehicle for pRML
spiking experiments are shown in SI Appendix, Fig. S2. While
nonspecific toxicity from normal brain at 10−3 concentration was
apparent, no additional toxicity was elicited by inclusion of high
concentrations of pRML. Collectively, these data demonstrate
that authentic ex vivo prions are not directly neurotoxic, either
when directly added to cell cultures or when first mixed with un-
infected brain homogenate to produce a prion titer at or far ex-
ceeding the prion titers of brain homogenate dilutions prepared
from clinically sick RML prion-infected mice which are highly
neurotoxic.
Sarkosyl Abolishes the Toxicity of RML-Infected Brain Homogenate
without Diminishing Infectious Prion Titer. In a further series of
experiments, and as a prerequisite for undertaking fractionation
of the toxic species from RML-infected brain homogenate, we
sought to identify a detergent that is compatible with preserva-
tion of toxic activity. Based on the knowledge that sarkosyl has
no detrimental effects on prion infectivity (20) we examined this
detergent first. Remarkably, we found that treatment of 10% (wt/vol)
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Fig. 2. Purified RML prions are not neurotoxic in primary cell culture. (A and B) Neurite length after treatment (designated by arrow) with pRML diluted in
tissue culture medium at 104.2 (n = 3), 105.2 (n = 3), 105.7 (n = 3), and 106.7 (n = 3) IU/mL or RML prion-infected brain (RML BH) at a concentration of 3 × 10−3 in
medium (105.7 IU/mL, n = 3) or uninfected brain at a concentration of 3 × 10−3 in medium (n = 3). (A) Normalized response over time, mean ± SEM, (B) at 72 h
post treatment, mean ± SD; *P < 0.05 (unpaired two-tailed t test). (C and D) Analysis of neurite fragmentation (C) and dendritic spine density (D) after
treatment with pRML in medium at 104.2 (n = 7), 105.2 (n = 7), 105.7 (n = 7), 106.7 IU/mL (n = 6), RML brain at a concentration of 10−3 in medium (105.2 IU/mL, n =
8), uninfected brain at a concentration of 10−3 in medium (n = 7) or medium alone (n = 8), mean ± SEM, *P < 0.05, ***P < 0.001, ****P < 0.0001. Gray
asterisks: comparison of RML BH to uninfected control BH, unpaired two-tailed t test. Black asterisks: comparison to medium only, one-way ANOVA with
Sidak’s correction for multiple comparisons; ns: not significant. (E) Representative images of dendritic spine density; green and red: raw imaging data; blue
and gray: image analysis. (Scale bar, 10 μm.)































sarkosyl completely abolished toxicity in primary cultured neurons
(Fig. 5 A–C and SI Appendix, Fig. S3) without diminishing the prion
infectivity titer in the same samples as measured by the ASCA
(Fig. 5D). Indeed, in accordance with previous findings (20), prion
infectivity levels in the RML brain homogenates treated with the
highest concentrations of sarkosyl were slightly higher than that of
untreated RML brain homogenate which might reflect changes in
infectious PrP rod aggregate size and number (21) or increased
bioavailability of prions following membrane solubilization. In
contrast to findings with RML brain homogenate, sarkosyl
treatment had no apparent effect on the nonspecific toxic effects
seen with high concentrations of normal brain homogenate (SI
Appendix, Fig. S3). Thus, while the specific toxicity of RML brain
homogenate is sarkosyl-sensitive, the nonspecific toxicity of
normal brain homogenate is not. Indeed, after sarkosyl treat-
ment the residual toxicity of RML brain homogenate becomes
equivalent to that produced by the same concentration of normal
brain homogenate (SI Appendix, Fig. S3). Collectively, these data
with sarkosyl clearly suggest that the structure of the specific
neurotoxic active species generated in RML-infected brain is
distinct from that of infectious prions.
Discussion
The molecular basis of prion neurotoxicity and neurodegeneration
remains unknown. Here we report a multiparametric assay of prion
neurotoxicity in primary neurons that readily differentiates prion-
infected and noninfected mouse brain homogenates. This assay is
a combination of kinetic and end-point high-content imaging of
neuronal morphology, and it measures neurite retraction, neurite
fragmentation, and changes in dendritic spine density upon semi-
acute treatment of 10-d-old cortico-hippocampal neuronal cultures
in a multiwell plate. The 2 log10 dynamic range of the assay enabled
us to undertake a systematic and quantitative investigation of prion
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Fig. 3. Purified RML prions in Prnp0/0 mouse brain homogenate are not neurotoxic in primary cell culture. (A and B) Neurite length after treatment (designated
by arrow) with pRML in Prnp0/0 BH at a concentration of 10−4 at 104.2 (n = 3), 105.2 (n = 3), 105.7 (n = 3), and 106.7 IU/mL (n = 3) or RML BH at a concentration of 3 ×
10−3 (105.7 IU/mL, n = 3), 10−4 (104.2 IU/mL, n = 3) or Prnp0/0 BH at 10−4 (n = 3). The same dataset for RML BH at concentrations of 3 × 10−3 and 10−4 is shown across
the figures for comparison with pRML. (A) Normalized response over time, mean ± SEM (B) at 72 h post treatment and mean ± SD pRML in Prnp0/0 BH (10−4) at
106.7 IU/mL is significantly less toxic than RML BH at 104.2 IU/mL (10−4). *P < 0.05, unpaired two-tailed t test. (C and D) Analysis of neurite fragmentation (C) and
dendritic spine density (D) after treatment with pRML in Prnp0/0 BH at a concentration of 10−4 at 104.2 (n = 3), 105.2 (n = 7), 105.7 (n = 3), and 106.7 IU/mL (n = 3) and
Prnp0/0 BH at a concentration of 10−4 (n = 8), RML BH at concentration of 10−4 (104.2 IU/mL, n = 5) and 10−3 (105.2 IU/mL, n = 8), or medium alone (n = 8), mean ±
SEM; comparison to Prnp0/0 BH at 10−4, one-way ANOVA with Sidak’s correction for multiple comparisons. *P < 0.05 and ***P < 0.001 ns: not significant. (E)
Representative images of dendritic spine density; green and red: raw imaging data; blue and gray: image analysis. (Scale bar, 10 μm.)























Using this multiparametric assay, we examined exceptionally
pure preparations of highly infectious, ex vivo prion rods [100 to
200 nm in length (21, 22)] devoid of contaminating proteins (20)
or small oligomeric PrP assemblies (21, 22) [akin to those de-
scribed by Prusiner and colleagues (1, 26)] in cell culture alongside
RML prion-infected mouse brain homogenates. We found that
prion-infected brain homogenates were toxic as measured by
neurite retraction and fragmentation as well as by reduction in
dendritic spine density. In sharp contrast, highly purified infectious
prion rods were not toxic and did not induce neurite retraction
even when at a 10-fold higher prion titer than that present in the
infected brain homogenate eliciting maximal toxicity. While highly
purified infectious RML rods correspond to PK-resistant material,
RML-infected brain homogenate (BH) comprises both PK-
resistant and PK-sensitive prion species (12–14, 20). We found
that a 30-min treatment of RML BH with increasing concentra-
tions of sarkosyl abolished neurotoxicity while infectivity was un-
affected or even slightly increased. Therefore, neurotoxicity does
not seem attributable to infectious prion assemblies regardless of
their aggregate size or relative protease sensitivity.
We do not consider these findings as contradictory to earlier
publications which have reported neurotoxicity in partially purified
prion preparations or crude prion-infected brain homogenate (7, 8),
which contains multiple PrP assemblies of different sizes and rela-
tive protease resistance, making it impossible to attribute toxicity to
a defined PrP species, infectious or otherwise. The lack of detect-
able direct toxicity of highly purified prion preparations or sarkosyl-
treated infected brain homogenate is consistent with models of
prion neurotoxicity being mediated by PrP species (PrPL), which are
distinct from fibrillar infectious prion assemblies and which may be
generated by a distinct mechanistic process (3, 4, 14, 15) although
further studies are required to confirm the identity of neurotoxic
species. In future work, these neurotoxicity assays will be applied to
study the kinetics of the generation of neurotoxic species during the
incubation period of prion infection and the biochemical proper-
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Fig. 4. Purified RML prions in Prnp+/+ mouse brain homogenate are not neurotoxic in primary cell culture. (A and B) Neurite length after treatment (des-
ignated by arrow) with pRML in Prnp+/+ BH at a concentration of 10−4 at 104.2 (n = 3), 105.2 (n = 3), 105.7 (n = 3), and 106.7 IU/mL (n = 3), uninfected Prnp+/+ BH
at a concentration of 10−4 (n = 3), or RML BH at concentrations of 10−4 (104.2 IU/mL, n = 3), 10−3 (105.2 IU/mL, n = 3), and 3 × 10−3 (105.7 IU/mL, n = 3). The same
dataset for RML BH at concentrations of 3 × 10−3 and 10−4 is shown across the figures for comparison with pRML. (A) Normalized response over time, mean ±
SEM, (B) at 72 h post treatment; mean ± SD pRML in Prnp+/+ BH (10−4) at 106.7 IU/mL is significantly less toxic than RML BH at 104.2 IU/mL (10−4); *P < 0.05,
unpaired two-tailed t test. (C and D) Analysis of neurite fragmentation (C) and dendritic spine density (D) after treatment with pRML in Prnp+/+ BH at a
concentration of 10−4 at 104.2 (n = 3), 105.2 (n = 7), 105.7 (n = 7), and 106.7 IU/mL (n = 3) and Prnp+/+ BH at a concentration of 10−4 (n = 8), RML BH at a
concentration of 10−4 (104.2 IU/mL, n = 5) and 10−3 (105.2 IU/mL, n = 8) or medium alone (n = 8); mean ± SEM, comparison to Prnp+/+ BH at 10−4, one-way
ANOVA with Sidak’s correction for multiple comparisons; ***P < 0.001; ns: not significant. (E) Representative images of dendritic spine density. Green and
red: raw imaging data; blue and gray: image analysis (Scale bar: 10 μm.)































prion-infected brain homogenate to isolate the neurotoxic species
and allow their identification and structural characterization.
Materials and Methods
All experimental procedures involving RML prions were carried out in mi-
crobiological containment level 2 or level 3 facilities with strict adherence to
safety protocols and guidelines. Work with animals was performed in ac-
cordance with licenses approved and granted by the UK Home Office (Project
Licenses 70/6454, 70/7274, and 70/9022) and conformed to University College
London institutional and Animal Research: Reporting of In Vivo Experiments
guidelines.
Prion Inoculation and Brain Homogenate Preparation. Mouse-adapted RML
prions used in this study were originally supplied by Charles Weissmann,
Zurich Institute for Molecular Biology. Two batches of 200 brains from ter-
minally affected intracerebrally inoculated CD1 mice (Hsd:ICR [CD1]; Harlan)
were homogenized in D-PBS lacking Ca2+ or Mg2+ ions (Invitrogen) using
tissue grinders as described previously (20) to produce two ∼1-L pools of
10% (wt/vol) RML brain homogenate (designated I13100 and I17700). Con-
trol 10% (wt/vol) BH was prepared in D-PBS from the brains of uninfected
CD1 (Prnp+/+) and FVB Prnp ablate (Prnp0/0) mice. All brain homogenates
were stored as aliquots at −70 °C.
Purification of Prion Rods from Brain Homogenate. Ex vivo infectious RML
prion rods were purified from 200-μL aliquots of 10% (wt/vol) of the RML
brain homogenates I13100 and I17700 without the use of Proteinase K as
described previously (20). The method produces a recovery of ∼10% of the
prions present in the starting 10% (wt/vol) brain homogenate so that
resuspension of the purified P4 pellet fraction in buffer at one-tenth of the
volume of the 10% (wt/vol) brain homogenate from which it was derived
produces prion preparations the infectivity titer of which is closely similar to
that of the starting 10% (wt/vol) brain homogenate (20). Concentration of
purified prions or buffer exchange was achieved by centrifugation at
16,100 × g for 30 min and resuspension of the pellet fraction into the desired
volume and buffer of choice. Typically, we prepared stock preparations
of the P4 pellet fraction resuspended in D-PBS containing 0.1% (wt/vol)
sarkosyl in one-fiftieth of the volume of 10% (wt/vol) brain homogenate
from which it was derived.
ASCA of RML Infectivity. The infectivity of purified RML prions and RML brain
homogenate was determined by ASCA in RML prion-susceptible PK1/2 cells
(27) as described (23). In brief, PK1/2 cells were dispensed into 96-well plates
at 18,000 cells per well. The next day the cells were infected with prion-
containing or mock samples using a Biomek FX liquid handling robot. Af-
ter 3 d of infection, cells were split 1:8 by Biomek FX and grown to con-
fluence for the next 3 d. After two further 1:8 splits, ∼25,000 cells were
transferred into each well of activated ELISPOT plates, which were then
treated with Proteinase K and developed using anti-PrP monoclonal anti-
body ICSM18 (D-Gen) and an alkaline-phosphatase–conjugated anti-IgG1
polyclonal secondary antibody (Southern Biotechnology Associates) as de-
scribed (23). Spot counts reporting PK-resistant PrP-positive cells were de-
termined with a Bioreader 5000-Eβ system (BioSys).
Quantification of Prion Titer. Enzyme-linked immunosorbent assay detection
of protease-resistant PrP on prion-infected cells on ELISPOT plates results in
the appearance of focal PrP “spots” distinct from any nonspecific back-
ground immunoreactivity seen on the plate (23, 27). The dose–response is
dynamic between ∼50 and 1,000 spots per well; however, because the assay
is nonlinear, every experiment must include serial dilution of RML prions of
known prion titer (intracerebral LD50 units/mL determined from rodent
bioassay) to produce a standard curve against which unknown samples can
be calibrated. This method reports prion titer in tissue culture infectious
units per milliliter, which in this paper for simplicity is abbreviated as
“IU/mL.” A stock 10% (wt/vol) RML brain homogenate I8700 used as a
reference preparation reported a prion titer of 107.2 intracerebral LD50
units/mL when end-point–titrated once in Tg20 mice (20). The infectious
titer of the 10% (wt/vol) RML BH stock (I13100) used in toxicity assays and
for prion purification was measured in ASCA as described above and was
107.2 IU/mL, consistent with previously determined titers of RML BH (14,
20). The infectious titer of four independently purified batches of prion
rods (P4 pellets resuspended in D-PBS containing 0.1% [wt/vol] sarkosyl in
one-fiftieth of the total volume of 10% [wt/vol] brain homogenate from
which the pellets were derived) was evaluated in an ASCA in PK1/2 cells (as
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Fig. 5. Toxicity of RML brain homogenate is abolished by increasing concentrations of sarkosyl while prion infectivity titer is fully preserved. RML BH (10%
[wt/vol]) was adjusted to final concentrations of 0.1 to 4% (wt/vol) sarkosyl (srk) in the sample, incubated at 37 °C for 30 min, and analyzed for acute toxicity
to primary neurons at a final brain concentration of 10−3.1 (A and B) and 10−4.1 (C). Infectivity of the sarkosyl-treated RML BH samples (C) was assessed si-
multaneously by using the ASCA (D). (A and B) Neurite length after treatment (designated by arrow) with RML BH at a concentration of 10−3.1 (n = 4). (A)
Normalized response over time (B) at 56 h post treatment; mean ± SD, **P < 0.01, ***P < 0.001, and ****P < 0.0001, comparison to medium, one-way ANOVA
with Sidak’s correction for multiple comparisons. ns: not significant. (C) Normalized response at 72 h post treatment (n = 3); mean ± SD, *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001, comparison to medium, one-way ANOVA with Dunnett’s multiple comparisons test. ns: not significant. (D) Infectivity titer of
RML BH treated with sarkosyl (n = 3) was determined by ASCA in PK1/2 cells after the third split. *P < 0.05, comparison to RML BH, one-way ANOVA with
Dunnett’s multiple comparisons test.























described above) and was equal to 107.9 ± 0.2 IU/mL and a specific prion in-
fectivity of 109.5 ± 0.2 IU/mg protein, consistent with previous findings (20).
Working Concentrations of Control and Prion-Infected Brain. RML and unin-
fected brain dilutions were prepared from 10% (wt/vol) stock homogenates.
As an example, a 10−3 concentration of brain was made by adding 10 μL of
10% (wt/vol) BH to 990-μL cell culture medium (a 10−3 concentration of brain
in tissue culture medium therefore corresponds to 100-fold dilution of 10%
[wt/vol] BH). As described above, the 10% (wt/vol) RML BH stock (I13100)
used in toxicity assays and for prion purification has an infectivity titer of
107.2 IU/mL or 108.2 IU/g brain. To facilitate easy correlation, the values of
RML brain concentration and corresponding infectivity titer (IU/mL) are
provided here: 10−1 (107.2), 10−2 (106.2), 3 × 10−3 (105.7), 10−3 (105.2), 10−4
(104.2), 10−5 (103.2), 10−6 (102.2), and 10−7 (101.2).
Detergent Treatment of Brain Homogenates. Sarkosyl (20% [wt/vol, pH 7.7])
was prepared from N-lauroylsarcosine (sarkosyl) sodium salt (Sigma, catalog
no. 61743) in sterile high-purity water. RML BH (10% [wt/vol]) or normal BH
(10% [wt/vol]) were adjusted to final concentrations of 0.1 to 4% (wt/vol)
sarkosyl in the sample and incubated at 37 °C with shaking at 300 × g in a
thermomixer for 30 min. Subsequently, samples were diluted in cell culture
medium and immediately analyzed for infectious titer in the ASCA in PK1/2
cells and for toxicity in primary neurons. The highest concentration of de-
tergent in brain homogenate applied to cultured neurons was 0.04%
(wt/vol) sarkosyl which had no intrinsic toxic effect on neuronal cells.
Primary neuronal culture. All of the reagents for primary neuron culture were
fromThermo Fisher Scientific unless indicated otherwise. Primary cortico-hippocampal
cultures for prion toxicity studies were prepared from embryonic day 17 FVB mouse
brains. Cortices and hippocampi were dissected in chilled dissection medium consist-
ing of calcium- and magnesium-free Hanks’s Balanced Salt Solution, 10 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 2 mM L-glutamine and 100
U/mL of penicillin–streptomycin. Brain tissue was next treated with 0.25% (wt/
vol) trypsin and 1,000 U of benzonase (VWR) for 15 min at 37 °C and washed
three times with dissection medium. Cells were then resuspended in the
plating medium consisting of Dulbecco’s Modified Eagle’s Medium supple-
mented with 10% (vol/vol) of heat-inactivated horse serum and 20 U/mL of
penicillin–streptomycin. Next, the cells were triturated with fire-polished glass
Pasteur pipettes with two different sizes of opening, filtered through 70-μm
strainers, counted using a disposable Neubauer hemocytometer (Labtech), and
plated out at 1.5 × 104 cells/well in poly-L-lysine-coated, black μ-clear
F-bottomed 96-well plates (Greiner) prefilled with warm plating medium.
Primary cells were left to settle for 1.5 h in a tissue culture incubator (37 °C,
5% CO2), and afterward the plating medium was changed to warm Neu-
robasal medium supplemented with 2% (vol/vol) B27, 0.25% (vol/vol) Glu-
taMAX, and 100 U/mL of penicillin–streptomycin. Primary cells were typically
used in the toxicity assays at the age of 10 d in vitro.
Immunofluorescence. Primary neuronal cultures grown in 96-well plates were
fixed in 3.6% (wt/vol) phosphate-buffered formaldehyde (100 μL/well) for
15 min, permeabilized for 5 min in 0.3% (vol/vol) TritonX100, 3% (wt/vol)
bovine serum albumin (BSA) (Sigma), and 5% (vol/vol) horse serum (HS)
(Thermo Fisher Scientific) in D-PBS (70 μL/well) and incubated with blocking
buffer (3% [wt/vol] BSA and 5% [vol/vol] HS in D-PBS; 70 μL/well) for 1 h at room
temperature. Anti-MAP2 mouse monoclonal antibody (1:400, Thermo Fisher
Scientific, catalog no. M13-1500) and anti-spinophilin/neurabin-II rabbit poly-
clonal antibody (1:500, Millipore, catalog no. 06–852) were added to the cells to
visualize neurites and dendritic spines, respectively. These antibodies were
applied to cells in antibody buffer (3% [wt/vol] BSA, 1% [vol/vol] HS and
0.1% [vol/vol] Triton X100; 50 μL/well) and left overnight at 4 °C. Cells were
then washed (2 × 100 μL D-PBS) and blocked (50 μL/well) with 5% (vol/vol)
normal goat serum (Invitrogen) in D-PBS for 45 min. Next, the cells were
incubated with secondary antibodies conjugated to Alexa Fluor dyes: goat
anti-mouse Alexa647 (Thermo Fisher Scientific, catalog no. A21235) and
goat anti-rabbit Alexa488 (Thermo Fisher Scientific, cat. No A11008) at a
dilution of 1:1,000 in antibody buffer for 1.5 h at room temperature. Cells were then
washed (2 × 100 μL D-PBS) and incubated with Alexa Fluor-555–conjugated anti-
NeuN mouse antibody to visualize neuronal nuclei (1:500, Millipore, catalog no.
MAB377A5, applied to cells in antibody buffer [50 μL/well] for 1 h at room
temperature). The cells were washed again (2 × 100 μL D-PBS), and 150 μL of
D-PBS was added to each well after the last wash. Then the plates were sealed
and stored at 4 °C in the dark. Plates were imaged within 1 wk of staining.
Image Acquisition. Images were acquired either with an IncuCyte S3 (Sarto-
rius) or Opera Phenix (Perkin-Elmer). For IncuCyte imaging, the imaging
platform was kept inside a tissue culture incubator at 37 °C and 5% CO2. A
total of four to nine images were taken per well with a 20× objective lens in
phase contrast every 4 h from the same well coordinates. For Opera Phenix
imaging, images of fixed, fluorescently stained cells were acquired with a
40× water immersion objective, and 15 views were taken per well. The laser
power and exposure time was optimized for each channel. Flat-field profiles
were calculated at imaging.
Image Analysis. Images taken on IncuCyte were analyzedwith the NeuroTrack
module, IncuCyte S3 v.2018B. Typical parameters used for the NeuroTrack
analysis were as follows: segmentation mode—brightness; segmentation
adjustment—1.2; neurite sensitivity—0.4; filtering—best; neurite width—2 μm.
All images collected on the Opera Phenix were run through Acapella analysis
scripts in Columbus (Perkin-Elmer). Flat-field correction was applied as the
starting point for all analyses. Neuron counts were made by segmenting
NeuN-positive nuclei using the “Find nuclei” function. Nuclear morphological
measurements: area (μm2) and roundness (perimeter form factor [Ff] calcu-
lated from a function of perimeter and area [Ff for a circle = 1, other shapes <
1]) were calculated using the “Calculate morphological properties” function
for each nucleus. Populations based on dimension were included and excluded
from further analysis by the “Select population” function. Populations of
nuclei smaller than 60 μm2 were designated as pyknotic. Populations of nuclei
with roundness of under 0.65 Ff were designated as fragmented or blebbing.
Neurons with nuclei that were classed as pyknotic or fragmented/blebbing
were considered dead and those that were not classed as pyknotic or frag-
mented/blebbing were considered healthy. Neurite fragmentation was esti-
mated from images by first identifying MAP2-postitive neurites using the
“Find image region” function. This region was then split into distinct objects.
The area of each MAP2 object was calculated in square micrometers, using the
“Calculate morphology properties” function. Fragments were selected using
the “Select population” function from the total object population if their area
was less than or equal to 20 μm2. All objects over 20 μm2 were considered
healthy neurites. The neurite fragmentation assay readout was the total
number of fragments per image divided by the total number of neurons in the
same image. Spinophilin-positive dendritic spines surrounding healthy neurites
were counted using the “Find image region” and “Find surrounding region”
functions in the spinophilin channel. Dendritic spines were then identified and
segmented using the “Find spots: method A” function, solely within the two
identified regions. The dendritic spine density assay readout was calculated as
the number of spines per micrometer of healthy neurites.
Statistical Analysis. The average neurite length value from the four to nine
images per well, acquired by IncuCyte, was found. There were at least three
technical replicates per treatment tested in three independent experiments
comprising independent cell cultures and independent prion preparations.
Neurite length was normalized to the baseline neurite length recorded for
∼20 h prior to the treatment (100%) on a per-plate basis. For Columbus image
analysis, analysis outputs of each image were averaged between 15 views of
each technical replicate. Then, an average was found between all of the
technical replicates from each independent test. For neurite fragmenta-
tion analysis, raw averages were normalized on a per-plate basis between
0 and 100% where 0% was the medium (negative control) and 100% was
the 10% (wt/vol) RML BH diluted 100-fold to a concentration of 10−3. For
dendritic spine density analysis, raw averages were normalized on a per-
plate basis to obtain a percentage difference from the negative control.
The mean and error of normalized values from all independent tests were
plotted. Error bar type, statistical test, and P value are stated in figure
legends. All statistical analyses were performed in GraphPad Prism 7.
Data Availability. The data that support the findings of this study are available
in the article and SI Appendix.
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